IRIDEX (IRIX) Competitors $0.96 +0.01 (+1.58%) As of 12:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRIX vs. HYPR, APYX, ZYXI, SURG, ICCM, TELA, APT, CTSO, SPAI, and MODDShould you be buying IRIDEX stock or one of its competitors? The main competitors of IRIDEX include Hyperfine (HYPR), Apyx Medical (APYX), Zynex (ZYXI), SurgePays (SURG), IceCure Medical (ICCM), TELA Bio (TELA), Alpha Pro Tech (APT), Cytosorbents (CTSO), Safe Pro Group Inc. Common Stock (SPAI), and Modular Medical (MODD). These companies are all part of the "medical equipment" industry. IRIDEX vs. Its Competitors Hyperfine Apyx Medical Zynex SurgePays IceCure Medical TELA Bio Alpha Pro Tech Cytosorbents Safe Pro Group Inc. Common Stock Modular Medical IRIDEX (NASDAQ:IRIX) and Hyperfine (NASDAQ:HYPR) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Is IRIX or HYPR more profitable? IRIDEX has a net margin of -22.79% compared to Hyperfine's net margin of -309.42%. Hyperfine's return on equity of -57.54% beat IRIDEX's return on equity.Company Net Margins Return on Equity Return on Assets IRIDEX-22.79% -192.95% -33.97% Hyperfine -309.42%-57.54%-50.38% Do analysts rate IRIX or HYPR? Hyperfine has a consensus target price of $1.06, suggesting a potential upside of 43.05%. Given Hyperfine's stronger consensus rating and higher probable upside, analysts plainly believe Hyperfine is more favorable than IRIDEX.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IRIDEX 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Hyperfine 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more volatility and risk, IRIX or HYPR? IRIDEX has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Does the MarketBeat Community prefer IRIX or HYPR? IRIDEX received 264 more outperform votes than Hyperfine when rated by MarketBeat users. Likewise, 62.10% of users gave IRIDEX an outperform vote while only 50.00% of users gave Hyperfine an outperform vote. CompanyUnderperformOutperformIRIDEXOutperform Votes27262.10% Underperform Votes16637.90% HyperfineOutperform Votes850.00% Underperform Votes850.00% Does the media refer more to IRIX or HYPR? In the previous week, IRIDEX had 5 more articles in the media than Hyperfine. MarketBeat recorded 7 mentions for IRIDEX and 2 mentions for Hyperfine. Hyperfine's average media sentiment score of 1.32 beat IRIDEX's score of 0.81 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IRIDEX 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in IRIX or HYPR? 20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 7.4% of IRIDEX shares are owned by company insiders. Comparatively, 31.0% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has stronger valuation and earnings, IRIX or HYPR? IRIDEX has higher revenue and earnings than Hyperfine. IRIDEX is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIRIDEX$48.80M0.33-$9.57M-$0.43-2.22Hyperfine$11.73M4.92-$44.24M-$0.54-1.37 SummaryIRIDEX and Hyperfine tied by winning 9 of the 18 factors compared between the two stocks. Get IRIDEX News Delivered to You Automatically Sign up to receive the latest news and ratings for IRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRIX vs. The Competition Export to ExcelMetricIRIDEXElectromedical equipment IndustryComputer SectorNASDAQ ExchangeMarket Cap$16.03M$3.37B$26.13B$8.57BDividend YieldN/A1.73%2.85%4.17%P/E Ratio-1.4319.3444.8419.81Price / Sales0.33206.131,697.25154.51Price / CashN/A46.8434.7434.64Price / Book1.623.876.894.65Net Income-$9.57M$95.96M$741.34M$248.05M7 Day Performance-1.87%7.96%0.55%-0.15%1 Month Performance-13.18%17.56%2.40%4.50%1 Year Performance-55.37%37.35%52,481.48%13.76% IRIDEX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRIXIRIDEX0.5308 of 5 stars$0.96+1.6%N/A-54.8%$16.03M$48.80M-1.43120News CoverageShort Interest ↑Gap UpHYPRHyperfine3.389 of 5 stars$0.85+41.1%$1.06+24.7%-14.8%$66.16M$11.73M-1.49190Positive NewsGap DownHigh Trading VolumeAPYXApyx Medical2.3734 of 5 stars$1.62+3.8%N/A+10.3%$61.23M$47.29M-1.95270News CoverageShort Interest ↓Gap UpZYXIZynex3.0239 of 5 stars$2.02-13.7%$6.00+197.0%-78.4%$61.08M$172.40M13.47770Positive NewsGap DownHigh Trading VolumeSURGSurgePays3.3055 of 5 stars$2.97+8.0%$8.75+194.6%-30.9%$60.62M$40.03M-2.6340Positive NewsICCMIceCure Medical3.2221 of 5 stars$1.05flat$2.50+138.1%+32.0%$58.28M$3.27M-3.6260TELATELA Bio2.4659 of 5 stars$1.42+2.2%$7.25+410.6%-67.1%$56.17M$71.22M-0.84120APTAlpha Pro Tech1.3737 of 5 stars$5.01+6.1%N/A-9.0%$54.43M$58.18M13.54120High Trading VolumeCTSOCytosorbents2.1035 of 5 stars$0.86+2.1%$5.50+541.0%+24.4%$53.72M$35.33M-2.38220News CoveragePositive NewsGap DownSPAISafe Pro Group Inc. Common StockN/A$2.90+10.7%N/AN/A$44.00M$2.05M-3.5811News CoverageGap UpMODDModular Medical1.7937 of 5 stars$0.79-8.2%N/A-54.5%$42.85MN/A-1.4920Upcoming Earnings Related Companies and Tools Related Companies HYPR Alternatives APYX Alternatives ZYXI Alternatives SURG Alternatives ICCM Alternatives TELA Alternatives APT Alternatives CTSO Alternatives SPAI Alternatives MODD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRIX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IRIDEX Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share IRIDEX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.